Antihemophilic Factor [Factor VIII]
Generic Details
Generic Name
Antihemophilic Factor (Factor VIII)
Other Names
- Factor VIII
- AHF
- Antihemophilic Factor A
Drug Class
- Coagulation Factor
Chemical Formula
Not applicable (Biological molecule)
Molecular Weight
Approximately 280 kDa
Mechanism of Action
- Antihemophilic Factor (Factor VIII) plays a crucial role in the blood clotting cascade by assisting in the conversion of Factor X to Factor Xa, ultimately leading to the formation of a stable blood clot.
Indications
- Hemophilia A (Inherited factor VIII deficiency)
Common Dosage Forms
- Lyophilized powder for reconstitution for intravenous injection
Typical Dosage
- The dosage is individualized based on the patient’s weight, severity of bleeding, and factor VIII levels. Dosage is measured in international units (IU) per kilogram of body weight.
Pediatric Dosage
- Similar to adult dosing but adjusted based on weight and age.
Geriatric Dosage
- No specific geriatric dosage adjustments are recommended
Side Effects
- Common side effects may include allergic reactions, development of inhibitors, and infusion site reactions.
Contraindications
- Known hypersensitivity to Antihemophilic Factor (Factor VIII) or its components.
Pregnancy Category
- Category C - Risk cannot be ruled out, benefits should outweigh risks.
Lactation Safety
- Limited data available; exercise caution or consider alternative treatments.
Drug Interactions
- No significant drug interactions reported
Overdose Symptoms
- Excessive doses can lead to thrombotic events
Antidote for Overdose
- Antithrombin III
Storage Conditions
- Store in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.
Pharmacokinetics
- Absorption: Following intravenous administration, Antihemophilic Factor (Factor VIII) is rapidly absorbed into the bloodstream.
- Distribution: Distributed mainly in the blood and taken up by endothelial cells.
- Metabolism: Metabolized by the liver.
- Excretion: Excreted via the reticuloendothelial system.
Precautions
- Monitor for allergic reactions during infusion.
Warnings
- Inhibitor development, thromboembolic events, and infusion site reactions may occur.
Others
- Regular monitoring of factor VIII levels is essential to adjust the dosage and prevent bleeding episodes.